Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.

Leukemia - 1 Aug 2010

von Bubnoff N, Rummelt C, Menzel H, Sigl M, Peschel C, Duyster J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to fms-Like Tyrosine Kinase 3
Share to Leukemia, Myelomonocytic, Chronic
Share to Niacinamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenylurea Compounds

Share to Pyrroles

Share to Sorafenib

Share to Sunitinib

Source

Identifiers

PMID: 20520641
DOI: 10.1038/leu.2010.122

Genes

FLT3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.PMID 20520641Read ↗

Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia.Semantic proximity Read ↗

Inhibition of FLT3 in AML: a focus on sorafenib.Semantic proximity Read ↗

Molecular Testing of FLT3 Mutations in Hematolymphoid Malignancies in the Era of Next-generation SequencingSemantic proximity Read ↗

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.Semantic proximity Read ↗

Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia.Semantic proximity Read ↗

Identification of a novel mutation of the FLT3 gene located on the juxtamembrane domain from acute myeloid leukemia patients.Semantic proximity Read ↗

Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.Semantic proximity Read ↗

Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia.Semantic proximity Read ↗

The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.Semantic proximity Read ↗

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.Semantic proximity Read ↗

FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.Semantic proximity Read ↗

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.